Why the study?
Does low-dose aspirin suppress the increased thromboxane biosynthesis in patients with polycythemia vera?
Population
17 patients with polycythemia vera and 23 gender- and age-matched controls (total n=40)
Comparison
Aspirin 50 mg/d for 7 to 14 days vs Gender- and age-matched controls
Design
Case-control
Follow-up
7 to 14 days
Authors
Loading...
May support low-dose aspirin in polycythemia vera; leaves open whether thromboxane suppression reduces clinical events in randomized trials.
Does low-dose aspirin suppress the increased thromboxane biosynthesis in patients with polycythemia vera?
In vivo platelet biosynthesis of TXA2 is significantly enhanced in polycythemia vera and can be effectively suppressed by low-dose aspirin.
Landolfi et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: